Lifeboat Foundation

Creating Smart Home Ecosystems — Enabling Health & Well-Being In Every Home — Viren Shah, VP & Chief Digital Officer, GE Appliances, Haier

Mr. Viren Shah is Vice President & Chief Digital Officer, at GE Appliances (GEA — https://www.geappliances.com/), the American home appliance manufacturer, now a majority owned subsidiary of the Chinese multinational home appliances company, Haier (https://www.haierappliances.com/).

Continue reading “Viren Shah — VP & Chief Digital Officer, GE Appliances (Haier) — Creating Smart Home Ecosystems” »

As the medical community’s understanding of the application of augmented intelligence (AI) in health care grows, there remains the question of how AI—often called artificial intelligence—should be incorporated into physician training. The term augmented intelligence is preferred because it recognizes the enhancement, rather than replacement, of human capabilities.

Understanding how AI can affect patients may help learners appreciate its relevance, he noted, adding that the National Board of Medical Examiners exam now tests physicians-in-training on health systems science, and there are questions about health care AI specifically.

But AI doesn’t just relate to systems issues. It also has a home within evidence-based medicine (EBM).

Continue reading “How health care AI could help train tomorrow’s physicians” »

A slew of new studies now shows that the area of the brain responsible for initiating this action — the primary motor cortex, which controls movement — has as many as 116 different types of cells that work together to make this happen.

The 17 studies, appearing online Oct. 6 in the journal Nature, are the result of five years of work by a huge consortium of researchers supported by the National Institutes of Health’s Brain Research Through Advancing Innovative Neurotechnologies (BRAIN) Initiative to identify the myriad of different cell types in one portion of the brain. It is the first step in a long-term project to generate an atlas of the entire brain to help understand how the neural networks in our head control our body and mind and how they are disrupted in cases of mental and physical problems.

“If you think of the brain as an extremely complex machine, how could we understand it without first breaking it down and knowing the parts?” asked cellular neuroscientist Helen Bateup, a University of California, Berkeley, associate professor of molecular and cell biology and co-author of the flagship paper that synthesizes the results of the other papers. “The first page of any manual of how the brain works should read: Here are all the cellular components, this is how many of them there are, here is where they are located and who they connect to.”

Despite high vaccine coverage and effectiveness, the incidence of symptomatic infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been increasing in Israel. Whether the increasing incidence of infection is due to waning immunity after the receipt of two doses of the BNT162b2 vaccine is unclear.

As the rollout of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)^1,2 is expanding worldwide, data on the durability of protection are limited. A randomized, controlled trial and real-world studies have shown vaccine efficacy of 94 to 95% with the BNT162b2 vaccine (Pfizer–BioNTech) and vaccine effectiveness in preventing symptomatic coronavirus disease 2019 (Covid-19) 7 days or more after receipt of the second dose of vaccine.^1,3–5 Real-world effectiveness and immunogenicity data describing the antibody kinetics over time after vaccination are beginning to appear, but a complete picture of the duration of immunity is not yet available. We recently reported that breakthrough infection in BNT162b2-vaccinated persons was correlated with neutralizing antibody titers.⁶ However, a threshold titer that can predict breakthrough infection has not been defined.

The BNT162b2 vaccine elicits high IgG and neutralizing antibody responses 7 to 14 days after receipt of the second dose. Lower antibody levels have been shown to develop in older persons, men, and persons with an immunosuppressed condition, which suggests that antibody titers in these populations may decrease earlier than in other populations.^7,8 A decrease in anti-spike (S) antibody levels by a factor of two was observed from the peak (at 21 to 40 days) to 84 days after receipt of the second dose of the BNT162b2 vaccine among 197 vaccinated persons.⁹ Here, we report the results of a large-scale, real-world, longitudinal study involving health care workers that was conducted to assess the kinetics of immune response among persons with different demographic characteristics and coexisting conditions throughout the 6-month period after receipt of the second dose of the BNT162b2 vaccine.

A FIVE-DAY COURSE of molnupiravir, the new medicine being hailed as a “huge advance” in the treatment of Covid-19, costs $17.74 to produce, according to a report (pdf) issued last week by drug pricing experts at the Harvard School of Public Health and King’s College Hospital in London. Merck is charging the U.S. government $712 for the same amount of medicine, or 40 times the price. (taxpayer funded mind you)

The Covid-19 treatment molnupiravir was developed using funding from the National Institutes of Health and the Department of Defense.

Exclusive: Report from planning exercise in 2016 alerted government of need to stockpile PPE and set up contact tracing system.

It probably didn’t feel like much, but that simple kind of motion required the concerted effort of millions of different neurons in several regions of your brain, followed by signals sent at 200 mph from your brain to your spinal cord and then to the muscles that contracted to move your arm.

At the cellular level, that quick motion is a highly complicated process and, like most things that involve the human brain, scientists don’t fully understand how it all comes together.

Continue reading “An ultra detailed map of the brain region that controls movement, from mice to monkeys to humans” »

There’s a lot of excitement at the intersection of artificial intelligence and health care. AI has already been used to improve disease treatment and detection, discover promising new drugs, identify links between genes and diseases, and more.

By analyzing large datasets and finding patterns, virtually any new algorithm has the potential to help patients — AI researchers just need access to the right data to train and test those algorithms. Hospitals, understandably, are hesitant to share sensitive patient information with research teams. When they do share data, it’s difficult to verify that researchers are only using the data they need and deleting it after they’re done.

Secure AI Labs (SAIL) is addressing those problems with a technology that lets AI algorithms run on encrypted datasets that never leave the data owner’s system. Health care organizations can control how their datasets are used, while researchers can protect the confidentiality of their models and search queries. Neither party needs to see the data or the model to collaborate.

With almost instant improvement.

A team of researchers from the University of California, San Francisco Health has successfully treated a patient with severe depression by targeting the specific brain circuit involved in depressive brain patterns and resetting them thanks to a new proof-of-concept intervention.

Continue reading “A New Brain Implant Relieved Treatment-Resistant Depression, in a World First” »